Oramed Pharmaceuticals, Inc. (ORMP) stock is higher by 231.24% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives ORMP stock a score of 71 out of a possible 100.
That rank is mainly influenced by a fundamental score of 90. In addition to the average rating from Wall Street analysts, ORMP stock has a mean target price of $33.75. This means analysts expect the stock to climb 121.02% over the next 12 months. ORMP's rank also includes a long-term technical score of 63. The short-term technical score for ORMP is 61.
ORMP has an Overall Score of 71. Find out what this means to you and get the rest of the rankings on ORMP!
Oramed Pharmaceuticals, Inc. (ORMP) stock is down -0.69% while the S&P 500 is higher by 0.7% as of 12:47 PM on Thursday, Dec 23. ORMP is down -$0.11 from the previous closing price of $15.38 on volume of 148,022 shares. Over the past year the S&P 500 is higher by 28.17% while ORMP is higher by 231.24%. ORMP lost -$0.78 per share in the over the last 12 months.
Click Here to get the full Stock Report for Oramed Pharmaceuticals, Inc. stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
